Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors

Kodiak Sells Capped Royalty Right on Global Net Sales of KSI-301 for $225 millionRoyalty Rate of 4.5% on Annual Net Sales Terminates after 4.5 times the Funded Amount Has Been PaidTransaction Enables an Immediate Acceleration of Clinical, Manufactu...Biopharmaceuticals, Ophthalmology
Kodiak Sciences